Asset profile
INS068
Peptide
Evidence outlook · lead readout
NCT05699408 · Type 2 Diabetes
The completed lead evidence is positive, with design limits that temper confidence; the rationale below says which.
NCT05699408: This Phase 3 trial randomly assigned 513 people with type 2 diabetes to insulin sudelidec or to insulin glargine, alongside their existing oral diabetes medicines. It was open-label, so treatment assignment was known throughout. HbA1c fell by 1.34 percentage points on insulin sudelidec against 1.37 on insulin glargine, a difference of 0.02 points (95% CI -0.14 to 0.18), meeting the prespecified test that it was not worse than glargine.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
80 competitors in this universe: 19 direct rivals (same mechanism and indication), 1 same-class, 60 same-indication; 33 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| INS068: this drug | Phase 3 | Peptide | Insulin receptor (basal) | ||
| Afrezza | Approved | Peptide | Insulin receptor (basal), Insulin | ||
| Insulin Degludec (Tresiba) | Approved | Peptide | Insulin receptor (basal) | ||
| Insulin Detemir (Levemir) | Approved | Peptide | Insulin receptor (basal) | ||
| Insulin Glargine (Lantus / Toujeo) | Approved | Peptide | Insulin receptor (basal) | ||
| Insulin Glulisine (Apidra) | Approved | Peptide | Insulin receptor (basal) | ||
| Insulin Icodec (Awiqli) | Approved | Peptide | Insulin receptor (basal) | ||
| Insulin Lispro (Humalog) | Approved | Peptide | Insulin receptor (basal) | ||
| LY2963016 (Basaglar) | Approved | Peptide | Insulin receptor (basal) | ||
| LY900014 (Lyumjev) | Approved | Peptide | Insulin receptor (basal) | ||
| SAR341402 | Approved | Peptide | Insulin receptor (basal) | ||
| GZR33 | Phase 3 | Peptide | Insulin receptor (basal) | ||
| IcoSema (Kyinsu) | Phase 3 | Peptide | Insulin receptor (basal), GLP-1 receptor | ||
| Insulin Efsitora Alfa | Phase 3 | Protein / enzyme therapeutic | Insulin receptor (basal) | ||
| ORMD-0801 | Phase 3 | Peptide | Insulin receptor (basal) | ||
| THDB0206 | Phase 3 | Peptide | Insulin receptor (basal) |
…and 65 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
13 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.